Skip to main
DTIL
DTIL logo

Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision Biosciences (DTIL) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precision BioSciences Inc. is experiencing notable progress in its partnered programs, which serve to further validate the clinical potential and versatility of its ARCUS genome editing platform across a variety of disease settings. The company boasts two wholly-owned ARCUS-based programs that are advancing well, supported by encouraging momentum from partner-led clinical validations. Additionally, impressive results have been observed in preclinical studies, with treated mice exhibiting up to 93% of maximum force output and a 66% improvement in resistance to eccentric injury, highlighting the platform's efficacy and potential applications in therapeutic contexts.

Bears say

Precision BioSciences is experiencing a decline in revenue, particularly due to the conclusion of collaborative agreements, including the Prevail/Lilly partnership, which has dampened financial performance and resulted in reduced cash balances. As of March 31, the company’s cash, cash equivalents, and restricted cash amounted to approximately $100 million, down from a prior estimate of $122 million, reflecting the negative impact of decreased revenue from key agreements as it approaches the end of its preclinical work. Additionally, while the company has secured a $2.5 million license agreement with TGTherapeutics related to CAR T therapy, the overall financial outlook remains challenged due to a reliance on partnerships and a slowing revenue stream as the company transitions through its developmental phases.

Precision Biosciences (DTIL) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precision Biosciences (DTIL) Forecast

Analysts have given Precision Biosciences (DTIL) a Buy based on their latest research and market trends.

According to 2 analysts, Precision Biosciences (DTIL) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precision Biosciences (DTIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.